Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL.
Kerstin WenzlMatt StokesJoseph P NovakAllison M BockSana KhanMelissa A HopperJordan E KrullAbigail R DropikJanek S WalkerVivekananda SarangiRaphael MwangiMaria OrtizNicholas StongC Chris HuangMatthew J MaurerLisa RimszaBrian K LinkSusan L SlagerYan AsmannPatrizia MondelloRyan MorinStephen M AnsellThomas M HabermannAndrew L FeldmanRebecca L KingGrzegorz NowakowskiJames R CerhanAnita K GandhiAnne J NovakPublished in: medRxiv : the preprint server for health sciences (2023)
This novel and integrative approach is the first to identify a signature at diagnosis that will identify DLBCL at high risk for early clinical failure and may have significant implications for design of therapeutic options.